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Clinical features of serous retinopathy 
observed with cobimetinib in patients 
with BRAF‑mutated melanoma treated in the 
randomized coBRIM study
Luis de la Cruz‑Merino1*, Lorenza Di Guardo2, Jean‑Jacques Grob3, Alfredo Venosa4, James Larkin5, 
Grant A. McArthur6,7, Antoni Ribas8, Paolo A. Ascierto9, Jeffrey T. R. Evans10, Antonio Gomez‑Escobar1, 
Giulio Barteselli11, Susan Eng11, Jessie J. Hsu11, Anne Uyei11 and Brigitte Dréno12
Abstract 
Background: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe 
the clinical features of serous retinopathy observed with cobimetinib in patients with BRAFV600‑mutated melanoma 
treated in the Phase III coBRIM study.
Methods: In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib 
and vemurafenib (n = 247) or vemurafenib (n = 246). All patients underwent prospective ophthalmic examinations 
at screening, at regular intervals during the study, and whenever ocular symptoms developed. Patients with serous 
retinopathy were identified in the study database using a group of relevant and synonymous adverse event terms.
Results: Eighty‑six serous retinopathy events were reported in 70 patients (79 events in 63 cobimetinib and vemu‑
rafenib‑treated patients vs seven events in seven vemurafenib‑treated patients). Most patients with serous retinopa‑
thy identified by ophthalmic examination had no symptoms or had mild symptoms, among them reduced visual  
acuity, blurred vision, dyschromatopsia, and photophobia. Serous retinopathy usually occurred early during cobi‑
metinib and vemurafenib treatment; median time to onset was 1.0 month. Most events were managed by observa‑
tion and continuation of cobimetinib without dose modification and resolved or were resolving by the data cutoff 
date (19 Sept 2014).
Conclusions: Cobimetinib treatment was associated with serous retinopathy in patients with BRAFV600‑mutated 
melanoma. Retinopathy was generally asymptomatic or mild. Periodic ophthalmologic evaluations at regular intervals 
and at the manifestation of any visual disturbance are recommended to facilitate early detection and resolution of 
serous retinopathy while patients are taking cobimetinib.
Trial Registration Clinicaltrials.gov (NCT01689519). First received: September 18, 2012
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Background
Aberrant activation of the mitogen-activated protein 
kinase (MAPK) pathway is commonly observed in human 
cancers [1]. Approximately 50% of cutaneous melanomas 
harbor mutations in the BRAF gene, resulting in consti-
tutive activation of the MAPK pathway [2, 3]. Combined 
BRAF and MEK inhibition enhances antitumor activity 
and may prevent or delay development of acquired resist-
ance by providing more potent inhibition of the MAPK 
pathway [4, 5]. In the coBRIM study, the combination of 
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cobimetinib, a MEK inhibitor, with vemurafenib, a BRAF 
inhibitor, significantly improved progression-free sur-
vival (PFS) [6] and overall survival (OS) [7] compared 
with placebo and vemurafenib (hereafter referred to as 
vemurafenib) in advanced BRAFV600-mutated melanoma.
A unique ocular adverse event (AE) resembling central 
serous retinopathy has been described with MEK inhibi-
tors [4, 8–13]. MEK-associated serous retinopathy mani-
fests bilaterally within days after inhibitor initiation [9, 
12, 14]. Patients may present with blurred or impaired 
vision, but many have no symptoms, with problems 
detected on ophthalmologic examination [9, 11]. Fundu-
scopic examination reveals a blunted foveal light reflex 
and often multiple foveal lesions [9]. Optical coherence 
tomography (OCT) is used to detect bilateral subfoveal 
neurosensory retinal detachments not associated with 
fluorescein angiography or indocyanine green angiogra-
phy, indicating unremarkable chorioretinal vasculature 
[9, 12].
In contrast, classic central serous retinopathy com-
monly manifests as unilateral metamorphopsia in 
middle-aged men, frequently associated with recent cor-
ticosteroid use or psychological stress [12, 15]. On fun-
duscopic examination, typical findings include round, 
well-delineated, shallow, serous macular neurosensory 
detachment, often surrounded by a halo light reflex. 
Vascular abnormalities are usually found on fluorescein 
and indocyanine green angiography, exhibiting single or 
multiple discrete leakage points that evenly distribute dye 
throughout the subretinal fluid [15]. OCT reveals neuro-
sensory detachment in addition to any associated retinal 
pigment epithelium detachment. The condition is typi-
cally self-limiting, and recovery of visual acuity is usually 
observed within 1–4 months without the need for treat-
ment [15].
It is clear that the pathophysiology of MEK inhibitor-
associated serous retinopathy is distinct from that of 
classic central serous retinopathy. Therefore, it is impor-
tant to further define this AE. This article describes the 
clinical features of serous retinopathy observed with 
cobimetinib in patients treated in the coBRIM study.
Methods
Study design and treatment
coBRIM was a multicenter, randomized, double-blind, 
parallel, placebo-controlled Phase III study designed 
to evaluate the safety and efficacy of cobimetinib com-
bined with vemurafenib, compared with vemurafenib, 
in patients with BRAFV600 mutation—positive unresect-
able locally advanced or metastatic melanoma. This trial 
was registered on clinicaltrials.gov as NCT01689519. 
The primary end point was investigator-assessed PFS. 
Secondary end points included OS, objective response 
rate, duration of response, PFS as assessed by independ-
ent review, safety, pharmacokinetics, and health-related 
quality of life (HRQOL). Complete methodology of the 
study and primary efficacy and safety results have pre-
viously been published and the protocol is available 
online [6]. The study was approved by the institutional 
review board or ethics committee at each participating 
institution and was conducted in accordance with the 
provisions of the Declaration of Helsinki and the Inter-
national Conference on Harmonisation guidelines for 
Good Clinical Practice. All the patients provided written 
informed consent.
Key eligibility criteria were age ≥18  years, histologi-
cally confirmed unresectable locally advanced stage IIIC 
or IV melanoma, BRAFV600 mutation detected using the 
cobas® 4800 BRAF V600 Mutation Test (Roche Molec-
ular Systems Inc. USA), no history of systemic therapy 
for advanced disease, measurable disease according to 
Response Evaluation Criteria In Solid Tumors version 
1.1, and Eastern Cooperative Oncology Group perfor-
mance status 0–1. Because of the known ocular toxicities 
associated with MEK inhibitors, patients with a history 
or ophthalmic examination evidence of a retinal abnor-
mality considered a risk factor for neurosensory reti-
nal detachment/central serous retinopathy, retinal vein 
occlusion, or neovascular macular degeneration were 
excluded. Patients also were excluded if they had risk 
factors for retinal vein occlusion, including uncontrolled 
glaucoma with intraocular pressure >21  mmHg, grade 
≥2 serum cholesterol, hypertriglyceridemia, or fasting 
hyperglycemia.
Patients were randomly assigned in a 1:1 ratio using 
an interactive response system [Perceptive Informat-
ics (now Parexel International), USA] to receive oral 
vemurafenib (960  mg twice daily) in combination with 
either placebo or oral cobimetinib (60  mg once daily 
for 21  days followed by 7  days off ). Treatment was 
administered in 28-day cycles and continued until dis-
ease progression, unacceptable toxicity, or withdrawal 
of consent. Patients were stratified according to the 
American Joint Committee on Cancer stage and geo-
graphic region. Dose modifications for management of 
specific adverse events were mandated by the protocol. 
For grade ≥2 visual symptoms, a complete ophthalmic 
examination was to be performed and treatment with 
cobimetinib combined with vemurafenib was to be 
interrupted until resolution to grade ≤1. Dose reduc-
tion of the implicated agent was employed if grade ≥2 
visual symptoms recurred. Treatment was to be per-
manently discontinued in the case of retinal vein occlu-
sion, lack of resolution of visual symptoms to grade ≤1 
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within 28 days, or recurrence of grade ≥2 visual symp-
toms despite dose reduction.
Ophthalmic assessments
Complete ophthalmic examinations were performed by 
a qualified ophthalmologist on all patients at screening 
and day 1 of cycle 2, then every three cycles until cycle 
11, every four cycles until cycle 23, every six cycles there-
after or when clinically indicated during the study, and 
at the end of study treatment visit (Additional file  1). 
Examinations included visual acuity testing, intraocular 
pressure measurements by tonometry, slit-lamp ophthal-
moscopy, indirect ophthalmoscopy, and OCT (time or 
spectral-domain).
Analysis
To ensure collection of all potential events, patients who 
experienced serous retinopathy were identified using a 
broad group of preferred terms from the Medical Dic-
tionary for Regulatory Activities (MedDRA) (Additional 
file 2) and record review from ophthalmologic examina-
tions. Events were graded according to the National Can-
cer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4.0 scale for eye disorders-
other (Additional file  3). NCI CTCAE version 4.0 does 
not have a severity grading scale for serous retinopathy. 
Results were presented and tabulated with descriptive 
statistics. The data cutoff date for this analysis was 19 
Sept 2014.
Results
Patients
Between January 2013 and January 2014, coBRIM 
enrolled 495 patients from 135 sites in the United States, 
Australia, New Zealand, Israel, and Europe. Of 495 ran-
domly assigned patients, one patient in each arm did not 
receive study treatment (Additional file 4); the remaining 
493 received cobimetinib combined with vemurafenib 
(n = 247) or vemurafenib (n = 246). At the time of data 
cutoff, the median follow-up duration for all patients was 
10.7 months.
Frequency and severity of serous retinopathy events
Serous retinopathy occurred in 63 of 247 cobimetinib 
combined with vemurafenib recipients (26%) (79 events), 
compared with seven of 246 vemurafenib recipients (3%) 
(7 events). In the cobimetinib combined with vemu-
rafenib arm, these events were usually reported as cho-
rioretinopathy (49%) and retinal detachment (33%) 
(Table  1). Serous retinopathy events were characterized 
by accumulation of subretinal fluid (Fig. 1). Most patients 
had no symptoms or had mild symptoms (grade 1; see 
Table  1). Most events were bilateral and were identi-
fied by surveillance ophthalmic examination. Grade 3–4 
serous retinopathy (Table 1) was identified in seven cobi-
metinib combined with vemurafenib recipients (11%); 
symptoms were present in all seven patients and included 
reduced visual acuity, blurred vision, dyschromatopsia, 
and photophobia.
Table 1 Frequency of adverse events by MedDRA preferred term
MedDRA Medical Dictionary for Regulatory Activities, AE adverse event, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
a Highest severity grade per patient
Cobimetinib + vemurafenib (n = 247) Placebo + vemurafenib (n = 246)
Total patients with serous retinopathy, n (%) 63 (25.5) 7 (2.8)
Total events, n 79 7
AE preferred term, n/N (%)
 Chorioretinopathy 31/63 (49.2) 1/7 (14.3)
 Retinal detachment 21/63 (33.3) 1/7 (14.3)
 Retinal pigment epithelium detachment 8/63 (12.7) 1/7 (14.3)
 Macular edema 5/63 (7.9) 1/7 (14.3)
 Macular fibrosis 2/63 (3.2) 1/7 (14.3)
 Retinal disorder 1/63 (1.6) 2/7 (28.6)
 Retinopathy 2/63 (3.2) 0
 Macular retinal pigment epithelium detachment 1/63 (1.6) 0
NCI CTCAE grade, n/N (%)a
 Grade 1 33/63 (52.4) 6/7 (85.7)
 Grade 2 23/63 (36.5) 1/7 (14.3)
 Grade 3 6/63 (9.5) 0
 Grade 4 1/63 (1.6) 0
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Fig. 1 Bilateral serous retinopathy (left eye shown) in a 64‑year‑old woman receiving cobimetinib combined with vemurafenib. At baseline, ophthal‑
mic examination findings were normal, and no retinal abnormalities were detected either on bidimensional near‑infrared image of the macula or on 
cross‑sectional optical coherence tomography scan across the fovea (first row). On study day 8, the patient had nonserious grade 2 bilateral blurred 
vision. On study day 10, ocular examination with indirect ophthalmoscopy revealed bilateral serous subfoveal neurosensory detachment (i.e. sub‑
retinal fluid). Retinal imaging showed that detachments of the neurosensory retina were not limited to the fovea but were multiple and extended 
across the macular area (second and third rows, white arrows). A diagnosis of nonserious grade 2 serous retinopathy was made, and no treatment was 
administered for this event. On study day 14, the event of neurosensory detachments was considered resolved on indirect ophthalmoscopy, and 
blurred vision was considered resolved on study day 15. On study day 21, retinal imaging confirmed resolution of the retinal abnormalities (fourth 
row). The investigator considered blurred vision and serous retinopathy to be related to cobimetinib combined with vemurafenib. Treatment with 
cobimetinib combined with vemurafenib was permanently discontinued on study day 36 because of other adverse events, including pyrexia, rash, 
and elevated liver enzyme levels, with consideration of the previous event of serous retinopathy
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Baseline characteristics of patients with serous retinop-
athy in the cobimetinib combined with vemurafenib arm 
were similar to those of the overall coBRIM population 
(Table  2). The frequency with which serous retinopathy 
developed in men and women in the cobimetinib com-
bined with vemurafenib arm was 59% and 41%, respec-
tively; classic serous retinopathy occurs predominantly in 
men [15].
Time to first onset of serous retinopathy
Median time to first onset of serous retinopathy in 
the cobimetinib combined with vemurafenib arm was 
1.0 month (range, 0.1–9.3 months). Most (63%) grade ≥2 
events occurred during cycle 1 (Fig. 2).
Management and resolution of serous retinopathy
Most patients with a first serous retinopathy event of 
grade 1 continued to receive cobimetinib without dose 
reduction (72%); it resolved in 38% of these patients 
(Table  3). In patients with grade 2 serous retinopathy 
(65%), doses were frequently reduced; it resolved in 92% 
of these patients. Grade 3–4 serous retinopathy was man-
aged by interruption or withdrawal of cobimetinib and 
was considered resolved or resolving at data cutoff; only 
one patient needed surgical treatment. This patient had 
grade 3 idiopathic rhegmatogenous retinal detachment of 
the right eye considered by the investigator to be unre-
lated to cobimetinib or vemurafenib. Although clinically 
distinct from serous retinopathy, it was included with 
the cases of serous retinopathy because retinal detach-
ment was included in preselected MedDRA preferred 
terms relevant to serous retinopathy (Additional file  2). 
This patient underwent pneumatic retinopexy, a surgical 
treatment for localized rhegmatogenous retinal detach-
ment, and the event was considered resolved on the day 
of surgery.
Overall, 52% of serous retinopathy events in the cobi-
metinib combined with vemurafenib arm had resolved at 
data cutoff. Of the resolved events, median time to reso-
lution was 1.2 months (range, 0.2–10.3 months).
Recurrent serous retinopathy
Fourteen patients with recurrent serous retinopathy were 
in the cobimetinib and vemurafenib arm. One patient 
experienced three recurrent episodes; the remaining 13 
experienced one recurrence each.
Most subsequent events were of the same or milder 
grade than the initial event; however, in three patients, 
initial and recurrent events were grade 1 and 2, respec-
tively. No recurrent events were grade ≥3. At the data 
cutoff date, half the recurrent events had resolved. No 
pattern emerged of action taken for recurrent events; 
patients continued taking cobimetinib combined with 
vemurafenib, therapy was interrupted, or therapy was 
withdrawn (four patients).
Discussion
This article describes clinical characteristics of serous 
retinopathy in patients treated with cobimetinib com-
bined with vemurafenib in the coBRIM study. Because 
all patients were prospectively screened for visual distur-
bances throughout the study, per protocol, most events 
were diagnosed early in the course of treatment, and 
most patients had no or mild symptoms at diagnosis.
The clinical relevance of surveillance ophthalmic exam-
inations is unclear. Most patients with serous retinopathy 
had no symptoms, did not require drug discontinuation 
or dose alteration, and did not experience greater sever-
ity of the condition over time. Patients with mildly symp-
tomatic (grade 2) serous retinopathy had dose reduction, 
resulting in resolution in the majority. For all but one 
patient (rhegmatogenous retinal detachment) with grade 
Table 2 Baseline characteristics of patients with serous retinopathy compared with the overall coBRIM population
SR serous retinopathy
Cobimetinib + vemurafenib recipi-
ents with SR (n = 63)
Placebo + vemurafenib recipients 
with SR (n = 7)
Overall coBRIM population (N = 493)
Age, years
 Median 59 62 55
 Range 30–78 33–76 23–88
Sex, n (%)
 Male 37 (58.7) 2 (28.6) 286 (57.8)
 Female 26 (41.3) 5 (71.4) 209 (42.2)
Region, n (%)
 Europe 51 (80.9) 5 (71.4) 366 (73.9)
 Australia/New 
Zealand
8 (12.7) 2 (28.6) 78 (15.8)
 North America 4 (6.4) 0 51 (10.3)
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≥3 serous retinopathy, dose interruption or withdrawal 
led to improvement without surgery. Few patients expe-
rienced recurrence despite continuing or restarting cobi-
metinib. All recurrent serous retinopathy events were 
either asymptomatic or mildly symptomatic, and half 
resolved by the time of data cutoff.
Based on the limited scientific literature available, 
characteristics of serous retinopathy observed with 
cobimetinib were similar to those of retinal changes 
observed with other MEK inhibitors [9, 11, 12, 14], 
suggesting that this is a class effect [11]. Symptomatic 
ocular toxicity, most commonly blurred vision, has been 
reported in 0–17% of patients treated with single-agent 
MEK inhibitors [16], whereas blurred vision and chori-
oretinopathy were reported in 0–2% and 1% of patients, 
respectively, treated with the combination of trametinib 
and dabrafenib [17, 18]. Higher incidences of ocular 
toxicity have been observed in trials incorporating pro-
spective screening, but the reported events are fre-
quently asymptomatic. Prospective screening identified 
retinopathy in 59% of patients treated with binimetinib, 
alone or in combination with RAF265 or encorafenib, 
Table 3 Cobimetinib dose modification after the first event of serous retinopathy in the cobimetinib plus vemurafenib arm
a Patients had events that were considered “recovering/resolving”
Action taken 
with cobimetinib
All patients with serous 
retinopathy events (n = 63)
Patients with grade 
1 events (n = 36)
Patients with grade 
2 events (n = 20)
Patients with grade 
3 events (n = 6)
Patients with grade 4 
events (n = 1)
All Resolved All Resolved All Resolved All Resolved All Resolved
Dose not changed, n 30 12 26 10 3 1 1 1 0 0
Dose reduced, n 18 16 4 3 13 12 1 1 0 0
Drug interrupted, n 10 5 5 3 2 0 3 2 0 0
Drug withdrawn, n 4 1 0 0 2 1 1a 0 1a 0
Unknown, n 1 0 1 0 0 0 0 0 0 0
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Fig. 2 First onset and severity grade of serous retinopathy in the coBRIM study, per patient
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with symptomatic events reported in 25% of patients 
[9], and 26% of patients treated with cobimetinib com-
bined with vemurafenib in the current study, with symp-
tomatic (grade ≥ 2) events in 12% of patients. Given the 
lack of prospective screening for retinopathy in other 
trials, incidence cannot be compared across MEK inhibi-
tors. Because of a lack of randomized trials and differ-
ences in the description and reporting of ocular toxicity 
across trials, it is unclear whether the combination of a 
BRAF inhibitor with a MEK inhibitor alters the inci-
dence of ocular toxicities compared with MEK inhibi-
tor monotherapy. However, in one small study, addition 
of the pan-RAF inhibitor RAF265 or the selective BRAF 
inhibitor encorafenib to the MEK inhibitor binimetinib 
did not appear to influence the incidence of retinopathy 
[9]. Furthermore, anecdotal data with binimetinib sug-
gest a temporal relationship between ocular toxicity and 
dose administration/blood binimetinib levels [9]. Further 
research is necessary to determine whether a similar rela-
tionship exists for other MEK inhibitors.
Although the MAPK pathway seems to play an impor-
tant role in maintenance, protection, and repair of the 
retina, pathophysiologic mechanisms underlying MEK 
inhibitor-induced retinopathy are not well understood 
[11]. The retinal pigment epithelium forms the outer 
component of the blood–retina barrier and controls sol-
ute and fluid permeability, a function critical for mainte-
nance of the specialized environment of the neural retina 
[19]; fluid accumulation between these layers can result 
in retinal detachment [11]. There is evidence that MAPK 
signaling regulates density of fluid transport channels 
(aquaporins) between retinal pigment epithelial cells [20]. 
Thus, MEK inhibition may alter permeability of the reti-
nal pigment epithelium, allowing accumulation of subret-
inal fluid. Further study is needed to test this hypothesis.
In other retinal diseases, the long-term presence of 
subretinal fluid can lead to photoreceptor death and per-
manent vision loss; therefore, persistent events may war-
rant treatment [15]. Understanding of the pathogenesis 
of classic central serous chorioretinopathy emphasizes 
the role of the choroid, which seems to be extremely 
permeable in this disease [15]. However, chorioretinal 
abnormalities are not observed in MEK inhibitor-asso-
ciated serous retinopathy, in which pathophysiology 
seems to result instead from altered permeability of the 
retinal pigment epithelium. Therefore, treatments that 
might promote subretinal fluid resolution in classic cen-
tral serous chorioretinopathy [15] may not be useful for 
subretinal fluid resolution in MEK inhibitor-associated 
serous retinopathy. It is reassuring that almost all cases 
of MEK inhibitor-associated serous retinopathy in the 
coBRIM study ultimately resolved either spontaneously 
or through dose modification.
In our experience, management of cobimetinib-associ-
ated serous retinopathy necessitates close collaboration 
with an ophthalmologist, and early involvement should 
be considered because most events occur within 1 month 
of treatment initiation. However, prospective screening is 
probably not warranted because surveillance ophthalmo-
logic examination typically identifies asymptomatic serous 
retinopathy. Ophthalmologic examination should be per-
formed periodically during cobimetinib treatment and as 
necessary for new or worsening visual disturbances. Tem-
porarily withholding or reducing the dose of cobimetinib 
should be considered upon diagnosis of serous retinopathy.
There are several limitations to our results. First, reli-
ance on AE reporting rather than ophthalmic (OCT) 
confirmation might have resulted in underreporting of 
asymptomatic or mildly symptomatic cases. Second, 
ophthalmic images were not prospectively centrally 
reviewed. Third, visual acuity was not measured in a 
standardized fashion across sites. Despite these limita-
tions, the large difference in rates of serous retinopathy 
between the cobimetinib combined with vemurafenib 
arm and the vemurafenib arm make it unlikely that 
results were caused by study limitations rather than the 
real effects of MEK inhibition with cobimetinib.
Conclusion
This report provides context around the guidance for the 
management of serous retinopathy in patients with unre-
sectable or metastatic melanoma with a BRAF V600E 
or V600K mutation receiving cobimetinib in combina-
tion with vemurafenib. Cobimetinib in combination with 
vemurafenib was associated with serous retinopathy 
in 26% of patients with BRAFV600-mutated melanoma. 
Although retinopathy was generally asymptomatic or 
mild and although most affected patients could safely 
continue to receive cobimetinib, dose interruption and 
dose reduction should be considered. Patients receiving 
cobimetinib should undergo ophthalmologic examina-
tion at regular intervals and whenever they experience 
symptoms suggestive of serous retinopathy. Additional 
examination may be warranted if symptoms persist. 
Guidance on the management of MEK-associated serous 
retinopathy can be found in the local prescribing infor-
mation where cobimetinib is approved.
Additional files
Additional file 1. Study drug dosing and ophthalmic examination 
schedule.
Additional file 2. MedDRA‑preferred terms relevant to serous 
retinopathy.
Additional file 3. NCI CTCAE v4.0 scale for eye disorders–other.
Additional file 4. CONSORT diagram.
Page 8 of 9de la Cruz‑Merino et al. J Transl Med  (2017) 15:146 
Abbreviations
MAPK: mitogen‑activated protein kinase; PFS: progression‑free survival; OS: 
overall survival; AE: adverse event; OCT: optical coherence tomography; 
HRQOL: health‑related quality of life; MedDRA: Medical Dictionary for Regula‑
tory Activities; NCI CTCAE: National Cancer Institute Common Terminology for 
Adverse Events.
Authors’ contributions
LCM, LG, JJG, AV, JL, GM, AR, TE, AGE, and BD conceived the study and wrote 
the manuscript. GB, SE, JS, and AU analyzed the clinical data. All authors criti‑
cally reviewed the final manuscript. All authors read and approved the final 
manuscript.
Author details
1 Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, 
Avenida Doctor Fedriani 3, 41071 Seville, Spain. 2 Fondazione IRCCS Istituto 
Nazionale dei Tumori, Milan, Italy. 3 Aix‑Marseille University, Hôpital de la 
Timone, Marseille, France. 4 Ospedale Monaldi, Naples, Italy. 5 Royal Marsden 
NHS Foundation Trust, London, UK. 6 Peter MacCallum Cancer Centre, East 
Melbourne, VIC, Australia. 7 University of Melbourne, Parkville, VIC, Australia. 
8 Jonsson Comprehensive Cancer Center at the University of California, Los 
Angeles, CA, USA. 9 Istituto Nazionale Tumori Fondazione G. Pascale, Naples, 
Italy. 10 Beatson West of Scotland Cancer Centre, University of Glasgow, Glas‑
gow, UK. 11 Genentech, Inc., South San Francisco, CA, USA. 12 Nantes University, 
Nantes, France. 
Acknowledgements
The authors thank the participating investigators, patients, and current and 
past members of the Roche and Genentech cobimetinib and vemurafenib 
teams. Third‑party medical writing assistance was funded by F. Hoffmann‑La 
Roche Ltd. and provided by Melanie Sweetlove, MSc, and Jennifer M. Kulak, 
PhD (ApotheCom, San Francisco, CA). Cobimetinib is being developed by 
Genentech, a member of the Roche Group, under a collaboration agreement 
with Exelixis. Vemurafenib is being developed by Genentech, a member of the 
Roche Group, under a collaboration agreement with Plexxikon.
Competing interests
This study was supported by F. Hoffmann‑La Roche Ltd, and several co‑
authors are employees of Roche/Genentech (GB, SE, JJH, AU). LC‑M has 
received research funding from, acted as a consultant/advisor for, and 
received travel funding from Roche. LDG has received honoraria and travel 
funds from Roche, Bristol‑Myers Squibb, and GlaxoSmithKline; and acted as a 
consultant/advisor to Italfarmaco. JG has received honoraria and travel funds 
from Roche, Bristol‑Myers Squibb, and GlaxoSmithKline; acted as a consultant/
advisor to GlaxoSmithKline, Bristol‑Myers Squibb, Roche, Amgen, Merck, and 
Novartis; received research funding from Roche and Bristol‑Myers Squibb; 
and received travel funding from Roche. GAM has received research funding 
from Pfizer, Celgene, and Ventana; acted as a consultant/advisor for Provectus; 
and received travel funding from Roche and Novartis. AR has stock or other 
ownership in Compugen, CytomX, Five Prime, and Kite Pharma; and has 
worked in a consulting/advisory role with Pfizer, Merck, Amgen, and Roche. 
PAA has received research funding from Array, Bristol‑Myers Squibb, Roche, 
and Ventana and acted as a consultant/advisor to Amgen, Array, Bristol‑Myers 
Squibb, Novartis, Merck Sharp & Dohme, Roche, and Ventana. TRJE has served 
on advisory boards for Bristol‑Myers Squibb, Baxter, Clovis, Eisai, GlaxoSmith‑
Kline, Celgene, Bayer, Roche, Genentech, Otsuka, and Karus Therapeutics; 
consulted for Bristol‑Myers Squibb, Celgene, Clovis, Baxter, GlaxoSmithKline, 
Eisai, Roche, Genentech, and Karus Therapeutics; received research funding 
from Astra Zeneca, Bristol‑Myers Squibb, Baxter, Bayer, Clovis, Celgene, Eisai, 
GlaxoSmithKline, Novartis, Otsuka, Roche Genentech, Merck, Verastem, 
Vertex, Immunocore, Basilea, Lilly, and Pharmamar; been on speakers bureaus 
for Bristol‑Myers Squibb, Celgene, GlaxoSmithKline, Roche, and Bayer; and 
received travel funding from Bristol‑Myers Squibb and Celgene. AG‑E, AV, and 
JL have no competing interests. BD has received research funding from Bristol‑
Myers Squibb and GlaxoSmithKline; worked in a consulting/advisory role for 
Bristol‑Myers Squibb, GlaxoSmithKline, Roche, and Novartis; been on speakers’ 
bureaus for Bristol‑Myers Squibb, GlaxoSmithKline, and Roche; and received 
travel funding from Bristol‑Myers Squibb and Roche.
Consent for publication
All the patients provided written informed consent.
Ethics approval and consent to participate
The study was approved by the institutional review board or ethics committee 
at each participating institution and was conducted in accordance with the 
provisions of the Declaration of Helsinki and the International Conference on 
Harmonisation guidelines for Good Clinical Practice. All the patients provided 
written informed consent.
Funding
F. Hoffmann–La Roche/Genentech sponsored the study. The primary analysis 
of this study (NCT01689519) was previously published by Larkin et al. [6]. 
Authors and their research teams were involved in the collection of data. 
Representatives of the sponsor collated the data and confirmed the accuracy 
of the data and analysis. The analysis was performed in collaboration with the 
authors. All the authors had full access to the data and analyses presented in 
this report.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 24 March 2017   Accepted: 15 June 2017
References
 1. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin 
Oncol. 2014;11(7):385–400.
 2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations 
of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.
 3. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, 
et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 
2005;353(20):2135–47.
 4. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski T, Daud A, et al. 
Combination of vemurafenib and cobimetinib in patients with 
advanced BRAFV600‑mutated melanoma: a phase 1b study. Lancet Oncol. 
2014;15(9):954–65.
 5. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, 
et al. Combined BRAF and MEK Inhibition versus BRAF inhibition alone in 
melanoma. N Engl J Med. 2014;371(20):1877–88.
 6. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Com‑
bined vemurafenib and cobimetinib in BRAF‑mutated melanoma. N Engl 
J Med. 2014;371(20):1867–76.
 7. Atkinson V, Larkin J, McArthur GA, Ribas A, Ascierto PA, Liszkay G, et al. 
Improved overall survival (OS) with cobimetinib (COBI)+ vemurafenib 
(V) in advanced BRAF‑mutated melanoma and biomarker correlates of 
efficacy. 12th International Congress of the Society for Melanoma Research, 
November 18‑21, San Francisco, CA; 2015. http://www.roche.com/dam/
jcr:b7f64a44‑c724‑4b2b‑8976‑9f33954f1492/en/med‑cor‑2015‑11‑23‑e.pdf.
 8. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, DeMarini 
DJ, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data 
for the oral MEK inhibitor trametinib: a phase 1 dose‑escalation trial. 
Lancet Oncol. 2012;13(8):773–81.
 9. Urner‑Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zubel A, et al. 
Transient MEK inhibitor‑associated retinopathy in metastatic melanoma. 
Ann Oncol. 2014;25(7):1437–41.
 10. Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, 
et al. Multicenter phase I trial of the mitogen‑activated protein kinase 1/2 
inhibitor BAY 86‑9766 in patients with advanced cancer. Clin Cancer Res. 
2013;19(5):1232–43.
 11. van der Noll R, Leijen S, Neuteboom GHG, Beijnen JH, Schellens JHM. 
Effect of inhibition of the FGFR‑MAPK signaling pathway on the develop‑
ment of ocular toxicities. Cancer Treat Rev. 2013;39(6):664–72.
 12. McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg 
ZA, et al. Bilateral subfoveal neurosensory retinal detachment associ‑
ated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 
2014;132(8):1005–9.
 13. Houde N, Faivre SJ, Awada A, Raymond E, Italiano A, Besse‑Hammer T, 
et al. Safety and evidence of activity of MSC1936369, an oral MEK1/2 
Page 9 of 9de la Cruz‑Merino et al. J Transl Med  (2017) 15:146 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
inhibitor, in patients with advanced malignancies. J Clin Oncol. 
2011;29:abstr 3019.
 14. Schoenberger SD, Kim SJ. Bilateral multifocal central serous‑like chori‑
oretinopathy due to MEK inhibition for metastatic cutaneous melanoma. 
Case Rep Ophthalmol Med. 2013;2013:673796.
 15. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretin‑
opathy: update on pathophysiology and treatment. Surv Ophthalmol. 
2013;58(2):103–26.
 16. Duncan KE, Chang LY, Patronas M. MEK inhibitors: a new class of chemo‑
therapeutic agents with ocular toxicity. Eye (Lond). 2015;29(8):1003–12.
 17. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, deBraud F, Larkin J, 
et al. Dabrafenib and trametinib versus dabrafenib and placebo for 
Val600 BRAF‑mutant melanoma: a multicentre, double‑blind, phase 3 
randomised controlled trial. Lancet. 2015;386(9992):444–51.
 18. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroia‑
kovski D, et al. Improved overall survival in melanoma with combined 
dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.
 19. Runkle EA, Antonetti DA. The blood‑retinal barrier: structure and func‑
tional significance. Methods Mol Biol. 2011;686:133–48.
 20. Jiang Q, Cao C, Lu S, Kivlin R, Wallin B, Chu W, et al. MEK/ERK pathway 
mediates UVB‑induced AQP1 downregulation and water permeability 
impairment in human retinal pigment epithelial cells. Int J Mol Med. 
2009;23(6):771–7.
